These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 29485006)

  • 21. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
    Brunton S; Reid TS
    Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.
    Ito H; Shinozaki M; Nishio S; Abe M
    Expert Opin Pharmacother; 2016 Oct; 17(15):2073-84. PubMed ID: 27592508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [SGLT2 inhibitors: a new therapeutic class for the treatment of type 2 diabetes mellitus].
    Dagan A; Dagan B; SegaL G
    Harefuah; 2015 Mar; 154(3):200-3, 210. PubMed ID: 25962253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
    Washburn WN
    Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
    Tsimihodimos V; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):399-408. PubMed ID: 27819144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):211-223. PubMed ID: 27817207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Euglycemic ketoacidosis : a complication of SGLT2 inhibitors].
    Mizuno A; Lolachi S; Pernet A
    Rev Med Suisse; 2017 May; 13(565):1164-1167. PubMed ID: 28639760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
    Alba M; Xie J; Fung A; Desai M
    Curr Med Res Opin; 2016 Aug; 32(8):1375-85. PubMed ID: 27046479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.
    d'Emden M; Amerena J; Deed G; Pollock C; Cooper ME
    Diabetes Res Clin Pract; 2018 Feb; 136():23-31. PubMed ID: 29196150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    J Pharmacol Sci; 2016 Jul; 131(3):198-208. PubMed ID: 27430987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
    Misra M
    J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].
    Insalaco M; Zanoli L; Rastelli S; Lentini P; Rapisarda F; Fatuzzo P; Castellino P; Granata A
    G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.
    Scheen AJ
    Clin Pharmacokinet; 2014 Apr; 53(4):295-304. PubMed ID: 24420910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
    Dailey GE
    Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.